SCHEMBL2929609

SCHEMBL2929609

CCN(CC)c1ccc2nc(Nc3cc(F)cc(F)c3)[nH]c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
POLB P06746 3/20 0.46
KDM4E B2RXH2 2/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
HPGD P15428 2/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
NPC1 O15118 2/20 0.46
GAA P10253 1/20 0.46
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
BRD4 O60885 1/20 0.43
CSNK1D P48730 6/20 0.42
CSNK1G2 P78368 6/20 0.42
CSNK1A1 P48729 5/20 0.42
GSK3B P49841 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931975 0.90 TERT (0.44) MEN1KMT2APOLBKDM4ELMNA
SCHEMBL2931537 0.84 POLB (0.53) MEN1KMT2APOLBKDM4ELMNA
SCHEMBL2926003 0.81 SMN1; SMN2 (0.43) MEN1KMT2APOLBKDM4ELMNA
SCHEMBL2925719 0.81 MEN1 (0.47) MEN1KMT2APOLBKDM4ELMNA
SCHEMBL14693571 0.78 POLB (0.40) POLBHTTNPC1RAB9ARIPK1
SCHEMBL14693610 0.78 POLB (0.40) POLBHTTNPC1RAB9ARIPK1
SCHEMBL2930206 0.76 RAB9A (0.43) MEN1KMT2APOLBKDM4ELMNA
SCHEMBL2932290 0.75 MAPT (0.47) MEN1KMT2APOLBKDM4ELMNA
SCHEMBL2931162 0.75 SMN1; SMN2 (0.44) MEN1KMT2APOLBKDM4ELMNA
SCHEMBL2932187 0.75 LMNA (0.64) MEN1KMT2APOLBKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820821-B2 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
US-20100152170-A1 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors TRANSTECH PHARMA, INC. (US) 2010-06-17 US disclosed
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors VTVX HOLDINGS I LLC 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152170-A1 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors AURKC, AURKA, AURKB MEN1 895/4885KMT2A 948/4885POLB 1990/4885
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors AURKC, AURKA, AURKB MEN1 895/4885KMT2A 948/4885POLB 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.